2022 Volume 31 Issue 1 Pages 93-101
Ever since our institution was inaugurated in 2005, we have been conducting types of prone mammography-guided vacuum-assisted breast biopsy (MMG-VAB) for non-palpable lesions found by calcification. Initially, MultiCare platinum (device A) was used to identify the Target coordinates in stereo photography, In January 2019, the Affirm Prone Biopsy System (device B) equipped with digital breast tomosynthesis began to be used. Was introduced. I gained experience using two types of MMG-VAB. For devices A and B, the EUREF's Average Glandular Dose (AGD) measurement method was modified to estimate the comparative AGD. From the comparative AGD, device B could be tested at low doses. The malignant lesion detection rate was the same for both devices A and B, with no significant difference. In device B, the number of alignment options increased and the tomosynthesis image made it easier to identify the target, and the collection success rate was high (p=0.04). In some cases, the hemostasis time was longer with device B (p<0.001), but the examination time was shorter than with device A (p<0.001). In some cases, it took a long time for the bleeding to stop when device B was used (p<0.001), but the examination time was shorter than that with device A (p<0.001), and the comparative AGD was also kept low, so that the burden on the patients could be reduced. Whether the examination can be performed accurately, safely, and quickly or not even if the equipment performance is improved depends on the alignment of the radiological technologist, and the role of the radiological technologist is considered to be important.
